Navigation Links
Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Date:12/17/2007

EDMONTON, Dec. 17 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX Venture Exchange: QPT) today announced that it has signed an agreement with a multinational technology development company (the "Investor") to receive $3,000,000 to develop oncology products based on its SonoLight Technology. Under the terms of the agreement, Quest Pharma Tech Inc. ("Quest" or the "Company") has already received $1,000,000; and the balance of $2,000,000 will be paid within the next twelve months. In return for this non-equity funding, the Investor who requested to remain anonymous, will receive 35 percent of all future net revenue from the commercialization of Quest's oncology products. This agreement does not preclude Quest from out-licensing the oncology applications of SonoLight Technology to a third party.

The Company's lead oncology product from the SonoLight platform, SL052, is anticipated to enter a Phase I clinical trial for photodynamic therapy treatment of prostate cancer during the second half of 2008. The Company is also evaluating the same technology for the treatment of lung cancer and peritoneal carcinomatosis.

"I can't think of a better holiday present to our shareholders than establishing an accelerated oncology development program," said Dr. Madi R. Madiyalakan, Chief Executive Officer of Quest Pharma Tech Inc. "We are optimistic about the potential of both our oncology products and our dermatology program. Additionally, we believe that our partnerships with Paramount BioSciences and KMH Co. Ltd. will help us achieve our long-term growth objectives, including share price appreciation."

About Quest PharmaTech Inc.

The Corporation is a publicly traded (TSX Venture Exchange: QPT), Alberta-based pharmaceutical company committed to build shareholder value through discovery, development, and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and dermatological conditions
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... , , , , , , , ... , AUDIO: , A team of scientists from...y of Arizona, Cold Spring Harbor Laboratory and Io...A of corn. The... , , Click here ... , , , , , , , ...
(Date:11/20/2009)...nd Latin American countries have an opportunity to... Researchers from the University of Valencia (UV),...e studied the productive fabric of the Spanish bio...n,s food and plant sectors have more clout than th...gy as applied to food and plants has been overlook...
(Date:11/20/2009)..., SAN DIEGO, Nov. 20 Veridiam (www...n the mid-size company category at the 2009 Workpl... the San Diego Society for Human Resources Managem... resources practices. ,, Veridiam was one of ni...ominated companies, honored at the recent awards c...
(Date:11/20/2009)..., SEATTLE, Nov. 20 Dend...that the U.S. Food and Drug Administration (FDA) p... amended Biologics License Application (BLA) for P...e. The FDA has assigned a Prescription Drug User ... it will respond to Dendreon,s amended BLA. Dendr...
Breaking Biology Technology:Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4Spanish biotechnology should focus on food and plant sectors to be more competitive 2Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3
... World,Heart Corporation ("WorldHeart") today anno...Agreement dated June 20, 2008 among WorldHeart, it..."), Abiomed, Inc.,("Abiomed"), Venrock Partners V,...epreneurs Fund V, L.P. (collectively, "Venrock"), ...ons Cayman Fund, L.P., Special,Situations Private ...
...asdaq: ATSI ), manufacturer and marketer of state... today announced Health Canada -- Medical,Device B... use of the ATS,Open Pivot(R) AP360(TM) Mechanical...-bin/prnh/20040202/ATSILOGO ), The ATS AP360 hea...new,supra-annular cuff design that facilitates imp...
...tion,(NYSE: SYK ) announced that it will host a c...p.m., Eastern Time, to discuss the Company,s opera...nd provide an operational,update. Operating result...ased at 4:00 p.m. that day., Stephen P. MacMillan...ergy, Vice President and Chief Financial Officer, ...
Other Biology Technology:WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing 2WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing 3WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing 4WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing 5WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing 6ATS Medical Announces Canadian Regulatory Approval of the ATS Open Pivot AP360 Mechanical Heart Valve 2Stryker To Host Conference Call On July 17, 2008 2
(Date:11/21/2009)...c newswire / - KINAXO Biotechnologies GmbH annou...two new investors in the company, Leifina and Conm...gen Schumacher has been elected as a new member of...ers Axel Ullrich, Hellmut Kirchner, Manfred Ferber...ountain Partners, BioM, High-Tech Grnderfonds, the...
(Date:11/20/2009)...entific and technological frontiers. The National ...hat totals nearly $4.3 million for the diverse eff...ican Recovery and Reinvestment Act of 2009. , ...stigation of solar phenomena. Philip R. Goode, dis...capabilities of NJIT,s Big Bear Solar Observatory ...
(Date:11/20/2009)...mber 2009 issue of the journal GENETICS ( http:/...of genes (1-aminocyclopropane-1-carboxylate syntha...f ethylene. This gas affects many aspects of plant...tion for future genetic manipulation that could ma...hrive in difficult terrain, increase yields, and o...
Breaking Biology News(10 mins):KINAXO Completes Financing Round to Enhance Biomarker Development 2KINAXO Completes Financing Round to Enhance Biomarker Development 3NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2It's a gas: New discovery may lead to heartier, high-yielding plants 2Top Five Global Pharmaceutical Company Names NewCardio as its Provider of Automated Thorough QT Solution 53191 1Top Five Global Pharmaceutical Company Names NewCardio as its Provider of Automated Thorough QT Solution 53191 2Top Five Global Pharmaceutical Company Names NewCardio as its Provider of Automated Thorough QT Solution 53191 3Top Five Global Pharmaceutical Company Names NewCardio as its Provider of Automated Thorough QT Solution 53191 4Eli Lilly 26 Company and ScinoPharm Taiwan Ltd Announce Settlement of Gemcitabine Litigation 13272 1Eli Lilly 26 Company and ScinoPharm Taiwan Ltd Announce Settlement of Gemcitabine Litigation 13272 2Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 1Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 2Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 3Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 4Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 5Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 6Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 7Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 8Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 9Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 10Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 11Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 12Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 13Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 14Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 15Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 16Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 17Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 18Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 19Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 20Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 21Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 22Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 23Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 24Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 25Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 26Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 27Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 28Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 29
...both UCLA and a team of enterprising UCLA scientis...ch and patient care. , In 1996, a unique collab... Belldegrun founded the biotechnology company Agen...million through an acquisition by Astellas Pharma ...ed private biotech firms poised to tackle therapeu...
...of Texas at Austin has received $1.9 million to ex...e national decisions about placement of devices to...partment of Homeland Security provided the funds t...ect smuggling in Russia and other countries of the...ty for their stores of nuclear weapons material an...
.... A ten-week expedition to the Lazarev Sea and the... Antarctic research season of the German research ...just some two hours after an official ceremony at ...arstern,s 25th anniversary of service, the researc...the Southern Ocean from Cape Town. The 53 scientis...
Other Biology News:Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc. 2Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc. 3Improving detection of nuclear smuggling goal of computer model of mechanical engineer 2Improving detection of nuclear smuggling goal of computer model of mechanical engineer 3Climate change and life in the Southern Ocean 2Climate change and life in the Southern Ocean 3Climate change and life in the Southern Ocean 4
Mouse Anti-Human S-100 alpha/beta chain Monoclonal Antibody, Unconjugated, Clone 8B10 from Santa Cruz Biotechnology, Inc.
Baker's yeast (S. cerevisiae) Phosphoglucose isomerase from Sigma-Aldrich
S-Protein Agarose from Novagen
ATX Ponceau S red staining solution from Sigma-Aldrich
Biology Products: